In particular, dysregulation of FGFR2 gene has been reported in thyroid, breast, lung, stomach, and pancreatic cancers, in which up- or down-modulation of KGFR expression has been observed in epithelial cells [3, 4, 8, 15], and in melanoma, where loss-of-function FGFR2 mutations have been detected in cancer specimens and cell lines [5]. This evidence concerns the gene FGFR2 and cancer.